Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

1 天前 · Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies are offering hope for more durable remissions and better quality of life. The lymphoma treatment landscape continues to evolve, with exciting advancements reshaping how ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

1 天前 · Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of early and accurate diagnosis, considering newer therapies like luspatercept, monitoring hemoglobin levels, and incorporating patient-reported outcomes to tailor individualized treatment plans for ...

1 天前 · Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) by considering factors such as efficacy data, …

2024年11月11日 · During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in differentiated thyroid cancer in the first article of a 2-part series.

2024年5月29日 · Loncastuximab Tesirine. The CD19-directed loncastuximab tesirine-lpyl (Zynlonta) gained an FDA orphan drug designation in 2017 7 and was granted accelerated approval in April 2021 for patients with large B-cell lymphoma. The approval was supported by the LOTIS-2 study (NCT03589469), which enrolled 145 patients who were relapsed/refractory to at least 2 prior treatments.

2024年10月6日 · Olomorasib/Pembrolizumab Shows Promising Response Rates in NSCLC. Olomorasib (LY3537982; 50 mg or 100 mg) plus pembrolizumab (Keytruda) showed favorable overall response rates in the first line setting for patients KRAS G12C–mutated metastatic non–small cell lung cancer, regardless of PD-L1 expression. These data are from the phase 1/2 LOXO-RAS-20001 study (NCT04956640) and presented at ...

In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a patient with multiple myeloma and progressive disease. Panelists discuss how to approach treatment decisions for a 74-year-old patient with transplant-ineligible newly diagnosed ...